English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18240/20438 (89%)
造訪人次 : 5456966      線上人數 : 1473
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34893


    標題: Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol
    作者: Lee, Wei-Chieh
    Lin, Yu-Wen
    Shih, Jhih-Yuan
    Chen, Zhih-Cherng
    Wu, Nan-Chun
    Chang, Wei-Ting
    貢獻者: Natl Sun Yat Sen Univ, Coll Med, Sch Med
    Chi Mei Med Ctr, Dept Internal Med, Div Cardiol
    Natl Cheng Kung Univ, Coll Med, Inst Clin Med
    Chi Mei Med Ctr, Dept Surg, Div Cardiovasc Surg
    Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
    Natl Sun Yat Sen Univ, Sch Med
    Natl Sun Yat Sen Univ, Coll Med, Doctoral Program Clin & Expt Med
    Natl Sun Yat Sen Univ, Ctr Excellence Metab Associated Fatty Liver Dis
    Chi Mei Med Ctr, Div Cardiovasc Med
    關鍵字: Apoptosis
    Atrial fibrillation
    Carvedilol
    Ivabradine
    Mitral regurgitation
    日期: 2024
    上傳時間: 2024-12-25 11:05:12 (UTC+8)
    出版者: WILEY PERIODICALS, INC
    摘要: Background Ivabradine, a medical treatment for heart failure (HF), reduces heart rate (HR) and prolongs diastolic perfusion time. It is frequently prescribed to patients with HF who have a suboptimal response or intolerance to beta-blockers. Degenerative mitral regurgitation (MR) is a valvular heart disease often associated with the development of HF and atrial fibrillation (AF). However, studies comparing the effects of ivabradine and beta-blockers on MR are lacking. Therefore, this study aimed to explore the potential therapeutic effects of ivabradine and carvedilol on MR using a rat model.Methods and results Using a novel echo-guided mini-invasive surgery, MR was created in 12-weeks-old Sprague-Dawley rats. After 2 weeks, the rats were randomized to receive either ivabradine or carvedilol for 4 weeks. Echocardiography was performed at baseline and at two-week intervals. Following haemodynamic studies, postmortem tissues were analysed. Notably, the MR-induced myocardial dysfunction did not improve considerably after treatment with ivabradine or carvedilol. However, in haemodynamic studies, pharmacological therapies, particularly carvedilol, mitigated MR-induced chamber dilatation (end-systolic volume and end-diastolic volume; MR vs. MR + Carvedilol; P < 0.05) and decreased compliance (end-systolic pressure-volume relationship; MR vs. MR + Carvedilol; P < 0.05). Compared with ivabradine, a shorter duration (MR vs. MR + Carvedilol; P < 0.05) and reduced inducibility (MR vs. MR + Carvedilol and MR vs. MR + Ivabradine; P < 0.05) of AF were observed in MR rats treated with carvedilol. Similarly, reduced cardiac fibrosis and apoptosis were observed in the MR rat model in the treatment groups, especially in those treated with carvedilol (MR vs. MR + Carvedilol; P < 0.01).Conclusions Although both ivabradine and carvedilol, at least in part, mitigated MR-induced chamber dilatation and decreased compliance, carvedilol had a better effect on reversing MR-induced cardiac fibrosis, apoptosis, and arrhythmogenesis than ivabradine. When compared with Ivabradine, MR rats treated with carvedilol exhibited a shorter duration and reduced inducibility of AF, thus providing more effective suppression of HCN4. Further investigations are required to validate our findings.
    關聯: Esc Heart Failure, v.11, n.1, pp.251-260
    顯示於類別:[行政單位] 456

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML2檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋